This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amgen To Highlight New Evolocumab (AMG 145) Data At Upcoming American Heart Association Scientific Sessions 2013

THOUSAND OAKS, Calif., Nov. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood 1, at the upcoming American Heart Association (AHA) Scientific Sessions 2013, being held Nov. 16 – 20 in Dallas.

Data from the Phase 2 OSLER ( Open Label Study of Long T ERm Evaluation Against LDL-C Trial) study, which evaluates the safety, tolerability and sustained efficacy of long-term administration of evolocumab and standard of care in more than 1,100 patients with high cholesterol, will be featured during a Clinical Science: Special Reports session on Tuesday, Nov. 19, at 4:51 p.m. CST.

"The Phase 2 OSLER study provides the first long-term 52-week data for a PCSK9 inhibitor in diverse patient populations with high cholesterol," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We hope the data we are accumulating from our Phase 3 clinical program for evolocumab will help advance care for patients who struggle to control high cholesterol and have an urgent unmet need."

Additionally, Amgen will highlight findings from long-term open-label data accumulated from patients in GAUSS ( Goal Achievement after Utilizing an anti-PCSK9 antibody in Statin intolerant Subjects) and MENDEL ( Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy For Easing Lipid Levels), two Phase 2 studies that evaluated evolocumab in patients with hyperlipidemia who cannot tolerate statins and as a stand-alone treatment, respectively.

Data presented on evolocumab will include:

  • Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-Term Administration of AMG 145 Versus Standard of Care in 1104 Patients: 52-Week Results from the OSLER Study  CS.03, Clinical Science: Special Reports, Tuesday, Nov. 19, 4:51 - 5:01 p.m. CST (Ballrooms C1 & C2)
  • Efficacy and Safety of Long-Term Treatment with AMG 145 Monotherapy Abstract 12191, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m. CST (Hall F, Core 2, Poster Board: 2010)
  • Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin IntoleranceAbstract 12621, Abstract Poster Session, Tuesday, Nov. 19, 3 - 4:30 p.m. CST (Hall F, Core 2, Poster Board: 2009)

Amgen will also host a webcast investor meeting at AHA on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.

Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs